| P50 | author | Tamara N Pereira | Q50896215 |
| | Tamara N Pereira | Q50896225 |
| P2093 | author name string | Grant A Ramm | |
| | Meagan J Walsh | |
| | Peter J Lewindon | |
| P2860 | cites work | Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain | Q22001492 |
| | Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors | Q24290397 |
| | TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4 | Q24314661 |
| | Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression | Q24336351 |
| | Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury | Q24554312 |
| | Expression of extracellular matrix proteoglycans perlecan and decorin in carbon-tetrachloride-injured rat liver and in isolated liver cells | Q24675872 |
| | Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study | Q24680285 |
| | Alagille syndrome and the Jagged1 gene | Q28211430 |
| | Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I | Q28242223 |
| | High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis | Q28308011 |
| | Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors | Q28360101 |
| | Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage | Q28506534 |
| | Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis | Q28568136 |
| | Lymphotoxin-beta receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury | Q28568720 |
| | Pro-fibrogenic potential of PDGF-D in liver fibrosis | Q28583234 |
| | A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis | Q29617241 |
| | Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration. | Q30480301 |
| | Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct | Q31921321 |
| | Liver involvement in cystic fibrosis. | Q33784011 |
| | Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. | Q33834255 |
| | Features of Alagille syndrome in 92 patients: frequency and relation to prognosis | Q33853650 |
| | Ursodeoxycholic acid for cystic fibrosis-related liver disease. | Q33909429 |
| | Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. | Q33938566 |
| | Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis | Q34033114 |
| | Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited | Q34146325 |
| | Endothelial dysfunction in cirrhosis and portal hypertension | Q34342993 |
| | Cytokine receptors and signaling in hepatic stellate cells | Q34391388 |
| | Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Q34544284 |
| | Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells | Q34580695 |
| | Liver disease in children with cystic fibrosis | Q34674329 |
| | p75 Neurotrophin receptor is a marker for precursors of stellate cells and portal fibroblasts in mouse fetal liver | Q34783190 |
| | The evolution of liver disease in cystic fibrosis. | Q35264319 |
| | Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease. | Q35272532 |
| | Evidence for altered hepatic matrix degradation in genetic haemochromatosis | Q35350790 |
| | Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury | Q35546843 |
| | Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. | Q40681279 |
| | Hepatic stellate cells | Q41368318 |
| | Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis | Q41416491 |
| | Ultrastructure of initial stages of perivenular fibrosis in alcohol-fed baboons | Q41816167 |
| | Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity | Q41867080 |
| | Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis | Q41933963 |
| | PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury | Q42488577 |
| | Interleukin-6 production by human liver (myo)fibroblasts in culture. Evidence for a regulatory role of LPS, IL-1 beta and TNF alpha | Q42513630 |
| | Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis | Q42991520 |
| | Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study | Q43036320 |
| | Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways | Q43269345 |
| | Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes | Q43514940 |
| | Pediatric-onset primary biliary cirrhosis | Q43599366 |
| | Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats | Q43720079 |
| | Plasma endothelin-1 level as a marker reflecting the severity of portal hypertension in biliary atresia | Q43784067 |
| | Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis | Q43814867 |
| | Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury | Q43821781 |
| | Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers | Q43878352 |
| | Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease | Q44022305 |
| | Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. | Q44028417 |
| | Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis | Q44198653 |
| | Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 |
| | The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo | Q44383140 |
| | Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression | Q44487653 |
| | Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration | Q44493296 |
| | Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors | Q44601242 |
| | Commitment of bone marrow cells to hepatic stellate cells in mouse | Q44738979 |
| | IL-2 receptor alpha deficiency and features of primary biliary cirrhosis | Q44814111 |
| | Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. | Q44927735 |
| | Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease. | Q45089361 |
| | Epidemiology of liver disease in cystic fibrosis: a longitudinal study | Q45175701 |
| | Serum type III procollagen and basement membrane proteins as noninvasive markers of hepatic pathology in Indian childhood cirrhosis | Q45205073 |
| | Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. | Q45952178 |
| | A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. | Q45965385 |
| | Relation between liver progenitor cell expansion and extracellular matrix deposition in a CDE-induced murine model of chronic liver injury. | Q46083765 |
| | IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis | Q46106529 |
| | Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment | Q46179802 |
| | Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance | Q46185466 |
| | Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor | Q46433708 |
| | Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers | Q46711380 |
| | Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis | Q46750005 |
| | Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy | Q46888119 |
| | Liver biopsy size matters in chronic hepatitis: bigger is better | Q47435383 |
| | A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis | Q47839389 |
| | Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. | Q50707385 |
| | In vivo immune modulatory activity of hepatic stellate cells in mice. | Q50710740 |
| | Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. | Q50722859 |
| | Genetic induction of proinflammatory immunity in children with biliary atresia. | Q51034487 |
| | The bone marrow functionally contributes to liver fibrosis. | Q51805517 |
| | Identification of vitamin A-free cells in a stellate cell-enriched fraction of normal rat liver as myofibroblasts. | Q52005235 |
| | Evidence for epithelial-mesenchymal transitions in adult liver cells. | Q52017440 |
| | Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. | Q53039947 |
| | Hepatic fibrosis scan for liver stiffness score measurement: a useful preendoscopic screening test for the detection of varices in postoperative patients with biliary atresia. | Q53501716 |
| | Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. | Q53538258 |
| | Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. | Q53540807 |
| | Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. | Q53547282 |
| | Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. | Q53928769 |
| | Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension | Q57003194 |
| | Role of TLR9 in hepatic stellate cells and experimental liver fibrosis | Q57083097 |
| | Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases | Q59946473 |
| | Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells | Q60571681 |
| | ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells | Q61763016 |
| | Expression of the thrombin receptor in human liver: Up-regulation during acute and chronic injury | Q61763075 |
| | Regulation of platelet-derived growth factor secretion and gene expression in human liver fat-storing cells | Q61763109 |
| | Hepatic progenitor cell-mediated regeneration and fibrosis: Chicken or egg? | Q61895894 |
| | The Bone Marrow and Liver Fibrosis: Friend or Foe? | Q62558142 |
| | Cystic fibrosis in adults: an autopsy study | Q67003501 |
| | Cholesterol 7 alpha-hydroxylase | Q67010992 |
| | Localization and cellular source of the extracellular matrix protein tenascin in normal and fibrotic rat liver | Q67534525 |
| | Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility | Q35553418 |
| | Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells | Q35569812 |
| | Transforming growth factor-beta in disease: the dark side of tissue repair | Q35603155 |
| | Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver | Q35604370 |
| | Portal tract fibrogenesis in the liver | Q35613002 |
| | The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease | Q35748097 |
| | Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia. | Q35753253 |
| | Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. | Q35915987 |
| | Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation | Q35941454 |
| | Increase in type I and type III collagens in human alcoholic liver cirrhosis | Q35985295 |
| | Mechanisms of liver fibrosis | Q36247948 |
| | Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved | Q36300686 |
| | Pathogenesis and treatment opportunities for biliary atresia | Q36352874 |
| | Neonatal liver disease | Q36459377 |
| | TLR9 in health and disease | Q36526346 |
| | Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. | Q36583579 |
| | Hepatic fibrosis, stellate cells, and portal hypertension | Q36680440 |
| | Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review | Q36804170 |
| | NOX in liver fibrosis | Q36832562 |
| | Optimizing diagnosis from the medical liver biopsy | Q36902218 |
| | Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species | Q36925116 |
| | Bile-acid-induced cell injury and protection | Q37157813 |
| | Targeting bile-acid signalling for metabolic diseases | Q37231731 |
| | Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells | Q37240288 |
| | CCR2 promotes hepatic fibrosis in mice | Q37249670 |
| | Expression of ECM proteins fibulin-1 and -2 in acute and chronic liver disease and in cultured rat liver cells | Q37308307 |
| | Hepatic lipocytes: the principal collagen-producing cells of normal rat liver | Q37558514 |
| | Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins | Q37921920 |
| | Liver disease and common-bile-duct stenosis in cystic fibrosis | Q39533300 |
| | Plasminogen activator inhibitors--a review | Q39605782 |
| | Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases | Q39630133 |
| | Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression | Q39974242 |
| | Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. | Q40092383 |
| | Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin | Q40310685 |
| | Proteasome inhibition induces hepatic stellate cell apoptosis | Q40324324 |
| | Pharmacology of ursodeoxycholic acid, an enterohepatic drug. | Q40571618 |
| | Role of mesenchymal cell populations in porcine serum-induced rat liver fibrosis | Q67589882 |
| | Biglycan and decorin gene expression in normal and fibrotic rat liver: cellular localization and regulatory factors | Q68184039 |
| | The changing epidemiology of cystic fibrosis | Q70528025 |
| | Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis | Q71011297 |
| | Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver | Q71466359 |
| | Vitamin A-poor lipocytes: a novel desmin-negative lipocyte subpopulation, which can be activated to myofibroblasts | Q71553060 |
| | Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases | Q71757372 |
| | Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury | Q72016100 |
| | Analysis of risk factors for the development of liver disease associated with cystic fibrosis | Q72274632 |
| | Natural history of liver disease in cystic fibrosis | Q73114499 |
| | Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells | Q73156216 |
| | Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis | Q73191758 |
| | Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment | Q73316077 |
| | Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis | Q73392099 |
| | Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: implications for pathogenesis | Q73420872 |
| | Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? | Q73517330 |
| | Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis | Q73589294 |
| | Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts | Q73746119 |
| | Immunohistochemistry of the liver and biliary tree in extrahepatic biliary atresia | Q74116070 |
| | Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension | Q74133484 |
| | Analysis of serum cytokine levels in primary biliary cirrhosis patients and healthy adults | Q74386488 |
| | Neonatal hepatitis--an autopsy study of 14 cases | Q74528908 |
| | Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) distribution in normal and pathological human bone | Q74594695 |
| | Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis | Q74610831 |
| | Ductular cell reaction in the liver in hepatic injury | Q74659453 |
| | Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis? | Q77579962 |
| | In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation | Q77807999 |
| | Characterization of matrix metalloproteinases in human urine: alterations during adolescence | Q77827128 |
| | Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1 | Q77932181 |
| | Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group | Q77958537 |
| | Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis | Q78053135 |
| | Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis | Q78069424 |
| | Early up-regulation of chemokine expression in fulminant hepatic failure | Q78962896 |
| | Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression | Q79209033 |
| | The role of monocyte chemoattractant protein-1 in biliary atresia | Q79425343 |
| | Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease | Q80146619 |
| | PI3K is involved in PDGF-beta receptor upregulation post-PDGF-BB treatment in mouse HSC | Q80312410 |
| | Serial circulating markers of inflammation in biliary atresia--evolution of the post-operative inflammatory process | Q80538951 |
| | Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease | Q81371688 |
| | Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice | Q81403844 |
| | Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts | Q81469007 |
| | Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis | Q82214451 |
| | Increased CXCR3 expression associated with CD3-positive lymphocytes in the liver and biliary remnant in biliary atresia | Q83294513 |
| | Chemokine (C-C motif) receptors in fibrogenesis and hepatic regeneration following acute and chronic liver disease | Q84820416 |
| P433 | issue | 2 | |
| P921 | main subject | liver disease | Q929737 |
| P304 | page(s) | 69-84 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | World journal of gastrointestinal pathophysiology | Q27723538 |
| P1476 | title | Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis | |
| P478 | volume | 1 | |